Citation Impact
Citing Papers
Oxidative Stress
2017 Standout
Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with Type 2 Diabetes
2009
Long-Lived C. elegans daf-2 Mutants Are Resistant to Bacterial Pathogens
2003 StandoutScienceNobel
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
2005 StandoutScience
Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators
2006 Standout
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer
2005 StandoutNobel
Sirtuins as regulators of metabolism and healthspan
2012 Standout
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
2010 StandoutNobel
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
2014
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Gene activities that mediate increased life span of C. elegans insulin-like signaling mutants
2007 StandoutNobel
Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy
2004 Standout
FoxO1 Regulates Multiple Metabolic Pathways in the Liver
2006
Impaired Regulation of Hepatic Glucose Production in Mice Lacking the Forkhead Transcription Factor Foxo1 in Liver
2007
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
2018 Standout
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
2006 Standout
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
AKT/PKB Signaling: Navigating Downstream
2007 Standout
Convergence of Peroxisome Proliferator-activated Receptor γ and Foxo1 Signaling Pathways
2003
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
2014
The metabolic syndrome
2010 Standout
Aquaporin water channels: molecular mechanisms for human diseases1
2003 StandoutNobel
Regulation of hepatic glucose metabolism in health and disease
2017
Modulation of oxidative stress as an anticancer strategy
2013 Standout
The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression
2001
FOXO transcription factors
2007
The changing landscape of atherosclerosis
2021 StandoutNature
mTOR at the nexus of nutrition, growth, ageing and disease
2020 Standout
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
2013
A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR
2002
SGLT inhibitors in management of diabetes
2013
Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy
2014
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
2020 Standout
The metabolic syndrome
2005 Standout
Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor
2015
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
2014
Non-alcoholic fatty liver disease
2021 Standout
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2017 Standout
Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
2014
Redox regulation of FoxO transcription factors
2015
Biochemical and cellular properties of insulin receptor signalling
2017
Type 2 diabetes
2017 Standout
mTOR: from growth signal integration to cancer, diabetes and ageing
2010 Standout
Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance
2011
Human aquaporin adipose (AQPap) gene
2002
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
2014
Cytosolic Phosphoenolpyruvate Carboxykinase Does Not Solely Control the Rate of Hepatic Gluconeogenesis in the Intact Mouse Liver
2007
Control of cell number by Drosophila FOXO: downstream and feedback regulation of the insulin receptor pathway
2003
FoxO proteins in insulin action and metabolism
2005
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
Programmed Cell Senescence during Mammalian Embryonic Development
2013 Standout
Thyroid Hormone T3 Counteracts STZ Induced Diabetes in Mouse
2011
Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology
2022 Standout
Insulin-induced Activation of Atypical Protein Kinase C, but Not Protein Kinase B, Is Maintained in Diabetic (ob/ob and Goto-Kakazaki) Liver
2004
FoxO1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization
2015
Genomic Structure and Insulin-mediated Repression of the Aquaporin Adipose (AQPap), Adipose-specific Glycerol Channel
2001
FOXO transcription factors at the interface between longevity and tumor suppression
2005
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
2003 Nature
AKT/PKB Signaling: Navigating the Network
2017 Standout
Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
2014
The Hallmarks of Aging
2013 Standout
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
2005 StandoutNature
Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress
2011 Standout
Mitochondria and cancer
2012 Standout
Peroxisome Proliferator-Activated Receptor γ Coactivator-1α, as a Transcription Amplifier, Is Not Essential for Basal and Hormone-Induced Phosphoenolpyruvate Carboxykinase Gene Expression
2004
Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans
2009 StandoutNobel
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
2015
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
2015
The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression
2001
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
2013
Chronic Kidney Disease Diagnosis and Management
2019 Standout
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c
2002
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Sirtuin 1 and Sirtuin 3: Physiological Modulators of Metabolism
2012
Myocardial Fatty Acid Metabolism in Health and Disease
2010 Standout
A Role of the Bile Salt Receptor FXR in Atherosclerosis
2010
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
DAF-16 Target Genes That Control C. elegans Life-Span and Metabolism
2003 StandoutScienceNobel
β-Selective C-Arylation of Silyl Protected 1,6-Anhydroglucose with Arylalanes: The Synthesis of SGLT2 Inhibitors
2015
The Genetics of Aging
2001 StandoutNobel
Genetic identification of HSD-1, a conserved steroidogenic enzyme that directs larval development inCaenorhabditis elegans
2008 StandoutNobel
Thyroid Hormone Regulation of Metabolism
2014 Standout
Forkhead transcription factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation
2003
β-Selective C-Arylation of Diisobutylaluminum Hydride Modified 1,6-Anhydroglucose: Synthesis of Canagliflozin without Recourse to Conventional Protecting Groups
2015
Critical nodes in signalling pathways: insights into insulin action
2006 Standout
Endoplasmic Reticulum Stress-Induced Activation of Activating Transcription Factor 6 Decreases cAMP-Stimulated Hepatic Gluconeogenesis via Inhibition of CREB
2009
Aquaglyceroporin AQP9: Solute permeation and metabolic control of expression in liver
2003 StandoutNobel
Regulation of hepatic fasting response by PPARγ coactivator-1α (PGC-1): Requirement for hepatocyte nuclear factor 4α in gluconeogenesis
2003
Hepatic Akt Activation Induces Marked Hypoglycemia, Hepatomegaly, and Hypertriglyceridemia With Sterol Regulatory Element Binding Protein Involvement
2003
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
2013
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
2015
Glucokinase and molecular aspects of liver glycogen metabolism
2008
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
2014
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
2014
Dapagliflozin in Patients with Chronic Kidney Disease
2020 Standout
Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial
2013
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
Regulation of PGC-1 Promoter Activity by Protein Kinase B and the Forkhead Transcription Factor FKHR
2003
Thyroid Hormone Promotes Postnatal Rat Pancreatic β-Cell Development and Glucose-Responsive Insulin Secretion Through MAFA
2013
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
2013
Atypical protein kinase C in insulin action and insulin resistance
2005
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
2014
The Many Forks in FOXO's Road
2003
Works of Rolf Grempler being referenced
Regulation of Glucose-6-phosphatase Gene Expression by Protein Kinase Bα and the Forkhead Transcription Factor FKHR
2000
Evidence for an indirect transcriptional regulation of glucose-6-phosphatase gene expression by liver X receptors
2005
Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
2011
Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats
2011
Empagliflozin, a novel potent and selective SGLT‐2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin‐induced diabetic rats, a model of type 1 diabetes mellitus
2012
Expression of Thyroid Hormone Receptor Isoform α1 in Pancreatic Islets
2003
Normalization of Prandial Blood Glucose and Improvement of Glucose Tolerance by Liver-Specific Inhibition of SH2 Domain–Containing Inositol Phosphatase 2 (SHIP2) in Diabetic KKAy Mice
2007
Inhibition of the interaction between protein phosphatase 1 glycogen-targeting subunit and glycogen phosphorylase increases glycogen synthesis in primary rat hepatocytes
2008
REGULATION OF GLUCOSE-6-PHOSPHATASE GENE EXPRESSION BY PROTEIN KINASE B AND THE FORKHEAD TRANSCRIPTION FACTOR FKHR
2001